NCT01510613View on ClinicalTrials.gov

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Primary Amyloidosis of Light Chain Type
Interventions
DRUG

Pomalidomide and Dexamethasone

Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity

Trial Locations (1)

27100

Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT01510613 - Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis | Biotech Hunter | Biotech Hunter